Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: The MYBL2–CCL2 axis promotes tumor progression and resistance to anti-PD-1 therapy in ovarian cancer by inducing immunosuppressive macrophages

Fig. 5

Inhibition of MYBL2 reduces resistance to anti-PD1 therapy in ovarian cancer. (A) MYBL2 knockdown reduces anti-PD1 resistance in orthotopic syngenetic model mice. (B) CVT-313 shows different effects on the MYBL2–CCL2 axis. (C) ID8 cells were injected into the left ovarian bursa. After 6 weeks, mice were treated with anti-PD1, CVT-313, or combination therapy. (D) Tumor volumes in the orthotopic syngenetic model mice. (E-G) The proportion of infiltrated CD11b + F4/80 + macrophages, expression of CD206 in macrophages, and ratio of CD4+/CD8 + T cells in ascites

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us